Anti-Mouse_Rat CD42d PE 25 ug
- Known as:
- Antibody toMouse_Rat CD42d PE 25 ug
- Catalog number:
- 12-0421-80
- Category:
- -
- Supplier:
- eBioscience
- Gene target:
- Anti-Mouse_Rat CD42d 25
Related genes to: Anti-Mouse_Rat CD42d PE 25 ug
- Gene:
- GP5 NIH gene
- Name:
- glycoprotein V platelet
- Previous symbol:
- -
- Synonyms:
- CD42d
- Chromosome:
- 3q29
- Locus Type:
- gene with protein product
- Date approved:
- 1993-11-03
- Date modifiied:
- 2016-01-14
Related products to: Anti-Mouse_Rat CD42d PE 25 ug
Related articles to: Anti-Mouse_Rat CD42d PE 25 ug
- Human papilloma virus (HPV)-related head and neck squamous cell carcinoma (HNSCC) incidence is rising. Despite the prognostic and therapeutic implication of HPV status, standardised detection methods are lacking. This study compared multiple HPV detection methods and evaluated the prognostic value of viral transcriptional activity in archival HNSCC tissues. - Source: PubMed
Publication date: 2026/09/04
Tornaas StianWang RuoyuEmblem Moe Svein ErikFromreide SirenElnour RammahKarlsdottir ÅsaBrydøy MarianneAarstad Hans JørgenVintermyr Olav KarstenRajpoot NasirKhurram Syed AliCostea Daniela ElenaDongre Harsh Nitin - Extensive-stage small cell lung cancer (ES-SCLC) is associated with a high symptom burden and impaired health-related quality of life (HRQoL). This prespecified analysis from the phase 3 DeLLphi-304 trial evaluated patient-reported outcomes (PROs) for tarlatamab versus standard-of-care (SoC) chemotherapy following first-line platinum-based therapy. - Source: PubMed
Publication date: 2026/08/13
Mountzios GiannisLammers Philip ESun LonghuaCho Byoung ChulDemirci UmutArulananda SureinGumus MahmutPunekar SalmanLugini AntonioZhu BoYu YanCiuleanu Tudor-EliadeAhn Myung-JuMazieres JulienSchuler MartinBlackhall FionaYoshida TatsuyaDirnberger FranziskaWang JessieHuang ShuangGauto DianaRudin Charles M - In this study, a recombinant adenovirus vaccine candidate constructed and evaluated to addressed the widespread clinical problem of co-infections of Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) and Porcine Circovirus Type 2 (PCV2). Epidemiological analysis revealed a PRRSV-positive rate of 40.8%, with prevalent strains belonging to Lineage 1 and Lineage 8. Analysis of key amino acid sites in the GP5 protein indicated the presence of highly virulent strain characteristics and widespread wild-type strain variation. Based on these findings and previous studies, we selected multiple PRRSV proteins (GP2-GP5, M, N) from multiple strains and the validated PCV2 Cap protein fused with dominant T/B cell epitopes, and successfully constructed four recombinant adenoviruses using a 2A peptide-linked strategy. These constructs stably expressed the target antigens in HEK293 cells and demonstrated good passage stability. Animal experiments showed that piglets immunized with the recombinant adenoviruses developed high levels of PRRSV- and PCV2-specific antibodies and neutralizing antibodies, and exhibited lymphocyte proliferation and secretion of cytokines including IFN-γ, IL-2, and IL-4, indicating the vaccine simultaneously elicited both humoral and cellular immune responses. Following PRRSV challenge, immunized groups, particularly the multi-antigen combined immunization group, demonstrated significant clinical protection. This study provides a promising vaccine candidate and a theoretical foundation for the coordinated control of PRRSV and PCV2. - Source: PubMed
Publication date: 2026/08/10
Li YuwanJi JunzhiWang KeWang ZequnWan JiaweiZhong JiahaoFeng JinChen JindingFan ShuangqiWu Keke - Non-muscle-invasive bladder cancer (NMIBC) is a chronic and recurrent condition requiring repeated intravesical treatments and lifelong surveillance, imposing a substantial burden on patients. Patient-reported outcomes (PROs) are increasingly required by regulatory bodies and HTA bodies to capture treatment impact from the patient perspective, yet no consensus on the optimal PRO instruments for use in NMIBC trials exists. This systematic review evaluated PRO instruments used in NMIBC and appraised their psychometric evidence using a structured evidence-maturity framework informed by the consensus-based standards for the selection of health measurement instruments (COSMIN) methodology. - Source: PubMed
Publication date: 2026/08/25
Griebsch IngolfShrestha SunilGotay Carolyn CGore John LCurtis FranBottomley Andrew - Porcine reproductive and respiratory syndrome virus (PRRSV) continues to pose a major challenge to swine production in Vietnam because of its rapid evolution and genetic diversity. Here, we analyzed 69 PRRSV-positive samples collected from 20 provinces in Vietnam between 2021 and 2026 using ORF5 gene sequencing to characterize the genetic diversity of circulating strains. Phylogenetic analysis demonstrated the co-circulation of multiple PRRSV-2 lineages (L1, L3, L5, L8, and L10), together with a limited presence of PRRSV-1, indicating a genetically diverse PRRSV population within the analyzed diagnostic samples. Among the PRRSV-2 strains, lineage 8 (L8), particularly sub-lineage L8E, was the most frequently detected, whereas lineage 10 (L10) accounted for 24.6% of the sequenced isolates and was detected only in samples collected from 2023 onwards. Independent maximum-likelihood phylogenetic and pairwise ORF5 distance analyses showed that the Vietnamese L10 strains formed a distinct monophyletic cluster within lineage 10. Analysis of the GP5 protein identified amino acid variation in previously described antigenic regions, providing descriptive information on the genetic diversity of circulating Vietnamese PRRSV strains. Collectively, these findings provide updated insights into the molecular epidemiology of PRRSV in Vietnam and highlight the value of continuous molecular surveillance for monitoring the emergence and distribution of PRRSV lineages. - Source: PubMed
Publication date: 2026/08/18
Mai Nguyen Tuan AnhGiang Tran Thi ChauHang Vu Thi ThuNgoc Trinh Thi BichNguyen Van TamVarga CsabaNguyen Thanh HJang GuehwanYou Su-HwaShin Yeon-KyungKim Jae-MyungKang Seok-JinLe Van Phan